Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Hansizhuang (serplulimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Fosun Pharma, Intas, PT Kalbe Farma

Drug class:

PD1 inhibitor

Related drugs:

‹

pembrolizumab (726)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab (84)

dostarlimab-gxly (42)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab (4)

geptanolimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

PD-1 knockout engineered T cells (0)

PF-07209960 (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

›

MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	serplulimab Sensitive: C1 - Off-label serplulimab Sensitive : C1	serplulimab Sensitive: C1 - Off-label serplulimab Sensitive : C1
PD-L1 expression	Head and Neck Cancer	PD-L1 expression	Head and Neck Cancer	serplulimab + HLX07 Sensitive: C2 – Inclusion Criteria serplulimab + HLX07 Sensitive : C2	serplulimab + HLX07 Sensitive: C2 – Inclusion Criteria serplulimab + HLX07 Sensitive : C2